Et si une seule administration permettait de traiter à la source certaines maladies cardiométaboliques sévères ? André Choulika était l'invité de @bfmbusiness pour échanger sur les nouvelles perspectives ouvertes par l'édition du génome: tinyurl.com/m8fwzhcm

Pourquoi arrêter un programme clinique qui venait d’obtenir le statut RMAT de la FDA ? André Choulika répond dans Le Journal des Biotechs de @Boursorama. Il y explique la transformation de Cellectis en société d’édition du génome in vivo >> shorturl.at/cbu8n

Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company. To read the press release: cellectis.com/en/press/celle…

Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business Update. To read the press release: cellectis.com/en/press/celle…

@cellectis announces participation in upcoming investor conferences. To read the press release: shorturl.at/lXN44

Cellectis Reports Financial Results for the Second Quarter 2026. To read the press release: cellectis.com/en/press/celle…

#Cellectis to Report Second Quarter Financial Results on August 6, 2026. Full press release here: cellectis.com/en/press/celle…

Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026. Read the full press release here: cellectis.com/en/press/celle…

Today at #EHA2026, we shared final Ph1 results from BALLI-01, evaluating lasme-cel in patients with r/r B-ALL. *100% ORR in the target Ph2 population (n=7) *All responding patients proceeded to transplant *Manageable safety profile Full press release: cellectis.com/en/press/celle…

Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL. To read the press release: cellectis.com/en/press/celle…

#Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026. Full press release here : cellectis.com/en/press/celle…

Cellectis announced two presentations at the @EHA_Hematology >> Lasme-cel - Oral presentation | June 13 >> Eti-cel - Poster presentation | June 13 To read the press release: cellectis.com/en/press/celle…

Cellectis Reports Financial Results for the First Quarter 2026. To read the press release: cellectis.com/en/press/celle…

Cellectis to report first quarter financial results on May 11, 2026. to read the press release: cellectis.com/en/press/celle…

Cellectis presents epigenetic editing platform to turn genes off without altering DNA at the American Society of Gene & Cell Therapy annual meeting. #ASGCT2026 To read the press release: cellectis.com/en/press/celle…

@cellectis highlights today's interim Phase 2 data for cema-cel. Cema-cel was originally developed by Cellectis as UCART19, the first allogeneic CAR-T program we ever built. Congrats to the teams at Allogene & Servier! To read the press release: lnkd.in/ethtUtXG

@cellectis Reports Full Year 2025 Financial Results and Provides a Business Update. To read the press release: cellectis.com/en/press/celle…

📢 Save the Date: @cellectis will report Q4 & FY 2025 results on March 19 🗓️ Mar 19 (Post-market): Earnings Release 🗓️ Mar 20 (8:00AM ET / 1:00PM CET): Earnings Call Join the webcast here: cellectis.com/en/press/celle… #Biotech #Earnings

Et si le temps n'était plus l'ennemi du patient ? ⏳ Pour un cancer agressif, chaque minute est un combat. Un traitement "sur étagères" est : déjà produit, congelé et prêt à l'emploi >> l'interview d'@AChoulika sur @bfmbusiness à 08:48min: shorturl.at/kDpqS

From Paris 🇫🇷 to New York 🇺🇸 to Raleigh 🇺🇸: One Team, One Mission.🎗️ On #WorldCancerDay, we celebrate 26 years of pioneering gene editing. We aren’t just building treatments, we are engineering the end of the wait for patients. Together, we edit the future.